Insud Pharma inaugrates Oligonucleotides Centre in India

This new plant will be capable of producing a novel antisense Oligonucleotide for the treatment of Spinal Muscular Atrophy.

Published On 2023-09-17 07:30 GMT   |   Update On 2023-09-17 07:31 GMT

Hyderabad: Insud Pharma, a leading Spanish multinational pharmaceutical company, has inaugurated its state-of-the-art Oligonucleotides Centre at its campus in Chemo India Formulation Private Limited, a wholly-owned subsidiary of Insud Pharma, here on Thursday.This is the first-of-its-kind research and production center in India, focused on Oligonucleotides research and commercial production,...

Login or Register to read the full article

Hyderabad: Insud Pharma, a leading Spanish multinational pharmaceutical company, has inaugurated its state-of-the-art Oligonucleotides Centre at its campus in Chemo India Formulation Private Limited, a wholly-owned subsidiary of Insud Pharma, here on Thursday.

This is the first-of-its-kind research and production center in India, focused on Oligonucleotides research and commercial production, the Parma company said in a release here.
It also ranks among the top 5 globally, alongside brand companies, with a focus on the US, EU, and numerous global markets.
This facility has been inspected and approved by the US FDA, Spanish Health Agency, Drug Control General of India, and various international customers.
The center was inaugurated by Telangana Industries Minister Kalvakuntla Taraka Rama Rao.(KTR) in the presence.of Mr. Lucas Sigman, Insud Pharma Chief Executive Officer.
The company said that Oligonucleotide-based drugs represent the latest in medical technology. These drugs employ small nucleic acid molecules to interact with DNA or RNA, regulating gene expression and treating conditions such as neurodegenerative diseases.
This new plant will be capable of producing a novel antisense Oligonucleotide for the treatment of Spinal Muscular Atrophy (SMA).
The products developed and manufactured at this center will be exported to various global markets.
The facility will be located in Genome Valley, the premier Life Sciences hub in Asia.
Insud Pharma operates throughout the entire pharmaceutical value chain, delivering specialist expertise in scientific research, development, manufacturing, sales and marketing for a wide range of active pharmaceutical ingredients (APls), finished dosage forms (FDFs), branded pharmaceuticals for human and animal care and biopharmaceutical products to treat and prevent diseases across different therapeutic areas.
Insud Pharma is present at every level of the chemical and pharmaceutical industry through its business units Chemo, Exeltis, mAbxience and Algenex.

Read also: Strides Pharma Science Singapore arm secures USFDA tentative okay for HIV drug Dolutegravir

Tags:    
Article Source : UNI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News